Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Severe Losses • Equity Dilution RLAY has strong liquidity and low leverage, but minimal revenue, severe losses, heavy cash burn, dilution, and an elevated sales-based valuation create substantial investment risks.
Price Behavior
Key Price Behavior Insights: • Modest Monthly Gain • Recent Pullback • Neutral Momentum Support Level: $19.40; $18.30–$18.80 Resistance Level: $20.60–$20.75 RLAY gained 5.4% last month but closed below its 21-day average at $19.44, with support at $19.40 and $18.30–$18.80, resistance at $20.60–$20.75, and downside risk increasing below $19.40.
Sentiment & News
Key News Insights: • Earnings Miss • Phase 3 Planned • Stake Increased Relay Therapeutics matched loss estimates at $0.41 per share but missed revenue expectations, while its planned Phase 3 breast-cancer trial and Bank of America's increased stake provide positive pipeline and investor signals.
AI Summary
RLAY should be viewed as a cash-funded but highly speculative clinical-validation bet, with a timely, successful Phase 3 launch in 2027 as the key upside catalyst and further dilution plus unproven efficacy as the main risks to monitor.
Description
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental methods to improve small-molecule discovery, initially concentrating on targeted oncology and genetic disease indications. Its clinical programs include an FGFR2 inhibitor (RLY-4008) in first-in-human testing, a mutant PI3Ka inhibitor program (RLY-2608), and an SHP2 inhibitor (RLY-1971) in Phase 1, and the company maintains research collaborations with D. E. Shaw Research for protein-motion modeling and with Genentech for development and commercialization of RLY-1971. Founded in 2015, Relay Therapeutics is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | RLAY | Relay Therapeutics, Inc. | Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events. | Closed | +12.2% |